Skip to content

Abatacept inhibits inflammation and onset of RA in individuals at high risk: ARIAA

One-paragraph summary

ARIAA randomized ACPA-positive people with arthralgia and MRI subclinical inflammation to six months of abatacept or placebo across 14 European centers. Abatacept improved the MRI inflammation endpoint and reduced/delayed progression to clinical RA during trial follow-up (PMID 38364841; ClinicalTrials.gov NCT02778906, live-verified 2026-08-30).

Key findings

  • Combined serologic, symptomatic and imaging enrichment selected a high-risk group.
  • A finite costimulation intervention altered subclinical inflammation.
  • Clinical progression was reduced/delayed over the observed period.
  • The trial validates preclinical RA as an interventional state.

Limitations

  • Enriched specialty-clinic risk does not transfer directly to population screening.
  • Delay and durable prevention are not equivalent.
  • Infection, treatment burden and overtreatment matter when treating people without arthritis.

Why it matters

ARIAA is a landmark transition from describing preclinical autoimmunity to testing causal immune interception before swollen joints appear.

Cited by wiki pages

  • overview
  • preclinical autoimmunity and prevention
  • clinical trials landscape